The Peptide Field. Cagrilintide: approval and evidence record.

Editorial review: 2026-08-30. Dataset version: 2026-09-11.1.

https://thepeptidefield.com/peptides/cagrilintide

Lookup: https://thepeptidefield.com/peptide-evidence-checker?peptide=cagrilintide#result

This is a dated editorial summary, not a live FDA check or independent medical review. It does not recommend treatment or verify a product in hand.

Status: Investigational in the United States; no FDA-approved cagrilintide product

Exact product limits: Cagrilintide has been studied alone and with semaglutide. CagriSema is the investigational combination of the two molecules. Results for that combination do not automatically apply to cagrilintide alone, and the name does not prove that an online product matches study material.

Human outcomes: Moderate. Randomized studies measured body-weight changes in people who received cagrilintide alone or with semaglutide. Each result has its own study limits.

Body effects in people: Moderate. A small study measured cagrilintide exposure and effects in people. It studied cagrilintide only with semaglutide, so it does not describe cagrilintide alone or every population.

What the evidence shows: A 26-week phase 2 study tested cagrilintide alone in adults without diabetes. It required body mass index (BMI), a height-and-weight measure, of 30 or higher. BMI 27 or higher also qualified with high blood pressure or unhealthy blood-fat levels. A later 68-week study used BMI 30 or higher, or 27 or higher with a weight-related health problem. Every group received food and activity guidance. It had separate cagrilintide, semaglutide, CagriSema, and placebo groups.

What remains unknown: FDA says cagrilintide is not a component of an approved drug and has not been found safe and effective for any condition. The reviewed records do not establish a complete long-term safety profile or show that online material matches study material. A trial record shows research information. It does not prove approval or availability.

Safety limits: An investigational molecule is not a self-treatment category. This guide does not provide trial-drug access, sourcing, dosing, injection, or combination instructions.

Approval claim: “Cagrilintide is FDA-approved.”
Verdict: Misleading. FDA's current page says cagrilintide is not a component of an approved drug and has not been found safe and effective for any condition. Human research does not equal FDA approval.
Evidence basis: Regulatory or product record. Scope: United States regulatory status as reviewed August 30, 2026.
Claim sources: https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss

Approval claim: “Cagrilintide can be compounded under federal law.”
Verdict: Misleading. FDA's current unapproved-GLP-1 page says cagrilintide cannot be used in compounding under federal law. This is a United States status statement, not a finding that every online product is identical or safe.
Evidence basis: Regulatory or product record. Scope: United States compounding status as reviewed August 30, 2026.
Claim sources: https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss

Sources used in the full review (a source is not support for every claim):

PubMed · The Lancet. Cagrilintide for weight management: randomized phase 2 trial. 2021. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/34798060/

PubMed · New England Journal of Medicine. Coadministered cagrilintide and semaglutide in adults with overweight or obesity. 2025. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/40544433/

U.S. Food and Drug Administration. FDA concerns with unapproved GLP-1 drugs used for weight loss. 2026. Accessed 2026-08-30. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss

ClinicalTrials.gov. Cagrilintide clinical study record. 2026. Accessed 2026-08-30. https://clinicaltrials.gov/study/NCT07220642

ClinicalTrials.gov. Phase 2 cagrilintide study record (NNC0174-0833). 2021. Accessed 2026-08-30. https://clinicaltrials.gov/study/NCT03856047

PubMed · Journal of Pharmacology and Experimental Therapeutics. AM833 pharmacology and cagrilintide identity. 2021. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/33727283/

PubMed · Journal of Medicinal Chemistry. Development of Cagrilintide, a Long-Acting Amylin Analogue. 2021. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/34288673/

PubMed · The Lancet. Cagrilintide with semaglutide: human exposure and effects. 2021. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/33894838/

Novo Nordisk. Q2 2026 research pipeline: NN9833 is cagrilintide. 2026. Accessed 2026-08-30. https://www.novonordisk.com/content/dam/nncorp/global/en/investors/pdfs/financial-results/2026/Q2-2026-Full%20presentation.pdf

U.S. Food and Drug Administration. FDA substance record: cagrilintide identity (not an approval record). 2026. Accessed 2026-08-30. https://precision.fda.gov/ginas/app/ui/substances/AO43BIF1U8

Keep the limits, review date, and sources with this record. Check the current source for changes.